Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, analyte specific reagents, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group B strep assays, ARIES group A strep assays, ARIES bordetella assays, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone512-219-8020
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$306.57 million
Profitability
Miscellaneous
Employees922
OptionableOptionable
Luminex (NASDAQ:LMNX) Frequently Asked Questions
What is Luminex's stock symbol?
Luminex trades on the NASDAQ under the ticker symbol "LMNX."
How often does Luminex pay dividends? What is the dividend yield for Luminex?
Luminex announced a quarterly dividend on Wednesday, December 12th. Investors of record on Thursday, December 20th will be paid a dividend of $0.06 per share on Thursday, January 10th. This represents a $0.24 annualized dividend and a dividend yield of 0.90%. The ex-dividend date is Wednesday, December 19th. View Luminex's Dividend History.
How were Luminex's earnings last quarter?
Luminex Co. (NASDAQ:LMNX) issued its earnings results on Monday, November, 5th. The medical instruments supplier reported $0.05 earnings per share for the quarter, missing analysts' consensus estimates of $0.08 by $0.03. The medical instruments supplier had revenue of $72.40 million for the quarter, compared to analysts' expectations of $74.05 million. Luminex had a net margin of 5.65% and a return on equity of 5.99%. The firm's revenue for the quarter was down 2.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.13 earnings per share. View Luminex's Earnings History.
When is Luminex's next earnings date?
How can I listen to Luminex's earnings call?
Luminex will be holding an earnings conference call on Monday, February 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
What guidance has Luminex issued on next quarter's earnings?
Luminex issued an update on its FY 2019 earnings guidance on Monday, January, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $337-343 million, compared to the consensus revenue estimate of $333.79 million.Luminex also updated its FY 2018 guidance to EPS.
What price target have analysts set for LMNX?
5 analysts have issued 12-month price objectives for Luminex's stock. Their predictions range from $22.00 to $33.00. On average, they anticipate Luminex's share price to reach $27.00 in the next year. This suggests a possible upside of 1.4% from the stock's current price. View Analyst Price Targets for Luminex.
What is the consensus analysts' recommendation for Luminex?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Luminex.
Has Luminex been receiving favorable news coverage?
Media headlines about LMNX stock have been trending somewhat positive on Saturday, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Luminex earned a news impact score of 0.9 on InfoTrie's scale. They also gave media stories about the medical instruments supplier a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the stock's share price in the near future.
Who are some of Luminex's key competitors?
Some companies that are related to Luminex include Insulet (PODD), Globus Medical (GMED), Novocure (NVCR), Integra Lifesciences (IART), Cantel Medical (CMD), Merit Medical Systems (MMSI), Tandem Diabetes Care (TNDM), NuVasive (NUVA), Glaukos (GKOS), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Atrion (ATRI), Nevro (NVRO), AtriCure (ATRC) and K2M Group (KTWO).
Who are Luminex's key executives?
Luminex's management team includes the folowing people:
- Mr. Nachum Shamir, CEO, Pres & Director (Age 65)
- Mr. Harriss T. Currie, CFO, Sr. VP of Fin. & Treasurer (Age 57)
- Mr. Richard W. Rew II, Sr. VP, Gen. Counsel & Corp. Sec. (Age 51)
- Mr. Todd C. Bennett, Sr. VP of Global Sales & Customer Operations (Age 49)
- Mr. Randall J. Myers, Sr. VP of Global Manufacturing & Quality (Age 57)
Who are Luminex's major shareholders?
Luminex's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Louisiana State Employees Retirement System (0.03%) and Meeder Asset Management Inc. (0.01%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Robert J Cresci and Todd C Bennett. View Institutional Ownership Trends for Luminex.
Which institutional investors are selling Luminex stock?
LMNX stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System and Meeder Asset Management Inc.. Company insiders that have sold Luminex company stock in the last year include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II and Todd C Bennett. View Insider Buying and Selling for Luminex.
How do I buy shares of Luminex?
Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Luminex's stock price today?
One share of LMNX stock can currently be purchased for approximately $26.62.
How big of a company is Luminex?
Luminex has a market capitalization of $1.17 billion and generates $306.57 million in revenue each year. The medical instruments supplier earns $29.42 million in net income (profit) each year or $0.91 on an earnings per share basis. Luminex employs 922 workers across the globe.
What is Luminex's official website?
How can I contact Luminex?
Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]
MarketBeat Community Rating for Luminex (NASDAQ LMNX)
MarketBeat's community ratings are surveys of what our community members think about Luminex and other stocks. Vote "Outperform" if you believe LMNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
